Research Associate and Project Staff

Careers

Current Research Associate and Project Staff opportunities are listed below.

Research Associate candidates will be expected to conduct research under the mentorship of a principal investigator in a predominantly independent manner. They will be expected to pursue testing of hypotheses by developing experimental designs, managing and processing data and interpreting and preparing results for publication in peer-reviewed journals. Research Associates will work closely with the principal investigator and will be expected to communicate effectively both in writing and in oral presentations. Qualified candidates will have successfully completed all requirements for the degree of doctorate in philosophy (PhD) or doctor in medicine (MD) in relevant scientific programs.

Project Staff candidates will have substantial experience at the Postdoctoral or Research Associate level and have established a respectable record of publication. They will work in collaboration with the principal investigator but work independently within the scientific framework of the principal investigator's laboratory. Project Staff may seek grant funding from extramural sources in support of their research projects with the consent of the principal investigator and department chair. This is a junior-level faculty position.

Please complete your application as directed and send to the investigator listed. We look forward to hearing from you!

# Date Contact Description
1 04/23/2022 Li Lily Wang
wangl9@ccf.org

Research Associate

 A Research Associate position is available in Dr. Li Lily Wang’s laboratory, in the department of Translational Hematology Oncology Research (THOR), https://www.lerner.ccf.org/thor/wang/  in the Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH. The Wang laboratory is engaging in cross-disciplinary studies by collaborating with basic and clinical researchers from LRI /CCF and the Case Comprehensive Cancer Center, affiliated with Case Western Reserve University.

Immune-checkpoint blockade (ICB) therapies have revolutionized the field of Cancer Immunotherapy. However, the low response rate in a majority of patients indicates the urgent need to identify and target additional checkpoint regulators. The Wang laboratory is among the first groups to demonstrate that the immune-checkpoint protein “V domain Immunoglobulin Suppressor of T cell Activation” (VISTA) is a promising target for cancer immunotherapy (1 – 6). Current projects are multi-disciplinary and involve elucidating the epigenetic and metabolic regulations by novel inhibitory receptors on tumor-associated cytotoxic T cells and tumor-associated macrophages or myeloid derived suppressor cells. We are also investigating the mechanisms of resistance following chimeric antigen receptor (CAR) T cell-based therapies in lymphoma patients.

We seek talented and committed candidates with a recent PhD and with research training and experience in Biochemistry, Cell Biology, and Immunology to join our team. Interested candidates should submit CV, a statement of research interests in a cover letter, and three references to Dr. Li Lily Wang, wangl9@ccf.org.

References:

 

  1.  Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L (2014) VISTA regulates the development of protective anti-tumor immunity. Cancer Research, 74:1933-1944. PMC4116689
  2. Wang L, Le Mercier I, Putra J, Chen W, Liu J, Schenk AD, Nowak EC, Suriawinata AA, Li J, Noelle RJ. (2014) Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. PNAS.  (41):14846-51 PMC4205642
  3. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller H, Guleria I, Barth RJ, Huang YH, Wang L (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. PNAS. 112(21):6682-7, PMC4450438
  4. Xu W, Tạ MH, Malarkannan S, Wang L(2018) Review: The structure, expression, and function of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular & Molecular Immunology. 2018 May 15(5):438-446 PMC6068175
  5. Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta H, Miller H, Olson M, Rajasekaran K, Ernstoff M, Wang D, Malarkannan S, Wang L (2019) Immune checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunology Research  PubMed PMID:31340983; NIHMSID:NIHMS1535762

 

 


2 04/23/2022 Li Lily Wang
wangl9@ccf.org

Postdoctoral Fellow

A Postdoctoral Research Fellow position is available in Dr. Li Lily Wang’s laboratory, in the department of Translational Hematology Oncology Research (THOR), https://www.lerner.ccf.org/thor/wang/  in the Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH. The Wang laboratory is engaging in cross-disciplinary studies by collaborating with basic and clinical researchers from LRI /CCF and the Case Comprehensive Cancer Center, affiliated with Case Western Reserve University.

Immune-checkpoint blockade (ICB) therapies have revolutionized the field of Cancer Immunotherapy. However, the low response rate in a majority of patients indicates the urgent need to identify and target additional checkpoint regulators. The Wang laboratory is among the first groups to demonstrate that the immune-checkpoint protein “V domain Immunoglobulin Suppressor of T cell Activation” (VISTA) is a promising target for cancer immunotherapy (1 – 6). Current projects are multi-disciplinary and involve elucidating the epigenetic and metabolic regulations by novel inhibitory receptors on tumor-associated cytotoxic T cells and tumor-associated macrophages or myeloid derived suppressor cells. We are also investigating the mechanisms of resistance following chimeric antigen receptor (CAR) T cell-based therapies in lymphoma patients.

We seek talented and committed candidates with a recent PhD and with research training and experience in Biochemistry, Cell Biology, and Immunology to join our team. Interested candidates should submit CV, a statement of research interests in a cover letter, and three references to Dr. Li Lily Wang, wangl9@ccf.org.

References:

 

  1.  Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L (2014) VISTA regulates the development of protective anti-tumor immunity. Cancer Research, 74:1933-1944. PMC4116689
  2. Wang L, Le Mercier I, Putra J, Chen W, Liu J, Schenk AD, Nowak EC, Suriawinata AA, Li J, Noelle RJ. (2014) Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. PNAS.  (41):14846-51 PMC4205642
  3. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller H, Guleria I, Barth RJ, Huang YH, Wang L (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. PNAS. 112(21):6682-7, PMC4450438
  4. Xu W, Tạ MH, Malarkannan S, Wang L(2018) Review: The structure, expression, and function of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular & Molecular Immunology. 2018 May 15(5):438-446 PMC6068175
  5. Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta H, Miller H, Olson M, Rajasekaran K, Ernstoff M, Wang D, Malarkannan S, Wang L (2019) Immune checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunology Research  PubMed PMID:31340983; NIHMSID:NIHMS1535762

 

 


3 03/03/2022 Sara Tavakoli
tavakos@ccf.org

Biological Safety Officer - Florida Research & Innovation Center

Cleveland Clinic Florida Research and Innovation Center (FRIC) is seeking a Biological Safety Officer who can be part of a dynamic and rapidly growing organization. The candidate will oversee the biosafety program, ensure compliance with applicable rules and requirements, and use data to develop corrective and preventative practices and procedures related to biosafety.  In addition, the candidate will serve as an expert resource and the implementation, management, and improvement of the Select Agent Program. 

As one of the world’s largest and busiest health centers, Cleveland Clinic is committed to delivering high quality programs of patient care, research, and education.  Cleveland Clinic’s Lerner Research Institute (LRI) researchers are at the forefront of biological discovery with research related to cancer, cardiovascular and metabolic diseases, brain and eye diseases, and diseases of inflammation and immune systems. With more than 1,500 researchers and support personnel in 190 laboratories across 11 departments and multiple centers, the Lerner Research Institute is one of the largest research institutes in the nation, consistently ranking in the top 10 in National Institutes of Health funding, a benchmark of research success. 

Additionally, the Lerner Research Institute has recently opened Cleveland Clinic Florida Research and Innovation Center (FRIC) which is dedicated to the discovery and advancement of innovative translational research, focused on immuno-oncology and infectious diseases.  The building is 3 floors with approximately 100,000 sq. ft. of dedicated research and support spaces.  The FRIC is developing state of the art Shared Resource Laboratories in Flow Cytometry, Imaging, Bioinformatics, Select Agents and a Vivarium. 

As a Biological Safety Officer, your responsibilities will be to:

  • Develop, implement, and direct a comprehensive biosafety program for the health system
  • Ensure organizational compliance with regulatory and sponsor requirements associated with biosafety
  • Supervise Cleveland Clinic biosafety professionals
  • Serve as a member of the Institutional Biosafety Committee (IBC) and assist the IBC Chair by interacting with investigators whose work is under review by committee, reviewing research protocols to ensure adequate biosafety measures are included, providing guidance to IBC on containment issues, implementing IBC-approved policies and plans, and providing administrative support
  • Maintain in-depth knowledge of biosafety principles and best practices and serve as a resource on related federal and state regulations
  • Provide technical guidance to caregivers regarding equipment, facilities and work practices for protection of personnel, laboratories and environment from biological hazards
  • Review experimental design, study protocols, procedures, and conduct risk assessments for research grant applications, material transfer agreements, research contracts, and research activities involving biohazardous agents and materials. These agents and materials may include recombinant or synthetic nucleic acid (rsNA), infectious agents, toxins, human-derived and nonhuman-derived materials, and human gene transfer clinical trials to ensure safe practices in support of the health system’s IBC, Institutional Animal Care and Use Committee (IACUC), and Institutional Review Board (IRB)
  • Ensure facility compliance with regulations and guidelines pertaining to use, handling, shipping, and disposal of potential biohazards and rsNA
  • Investigate accidents in regards to Biosafety issues and develop corrective action plans
  • Assist with investigations and reporting of non-compliance
  • Develop and implement emergency response procedures for incidents involving biohazardous agents and materials

Qualifications
Education

  • A Master of Science or Ph.D. in biological science (i.e., microbiology, bacteriology, virology etc.) or related field

Work Experience

  • Minimum 5 years experience in a biomedical research laboratory or related combination of education and experience. Experience in microbiology research is preferred.
  • Minimum 5 years experience in the field of biological safety in a biomedical research facility
  • Knowledge of NIH Guidelines, NIH/CDC BMBL guidelines, USG Policy for DURC, import and export programs (e.g. CDC IPP, APHIS, Bureau of Industry and Security), OSHA, and granting agency requirements
  • Experience working in or supervising BSL-3 containment research
  • Experience working with select agents or managing select agent research is preferred

Certifications

  • Certification or eligibility for certification by American Biosafety Association (ABSA) as a Registered Biosafety Professional or Certified Biological Safety Professional is preferred

Other requirements

  • Must achieve Department of Justice (DOJ) Security Risk Assessment (SRA) approval for working with select agents
  • Must obtain/maintain annual medical clearance through Cleveland Clinic’s Occupational Health Department to work in a BSL-3 Environment

Please send CV and cover letter to Sara Tavakoli at tavakos@ccf.org